The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats

European Journal of Pharmacology

Volumn 384, Issue 1, 1999, Pages 37-42

  Izzo, Angelo A ^a   Mascolo, Nicola ^b   Pinto, Luisa ^a   Capasso, Raffaele ^b   Capasso, Francesco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Cannabinoid; Defaecation; Diarrhoea; Intestinal motility; Intestinal secretion; Small intestine

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID CB1 RECEPTOR BLOCKING AGENT; CANNABINOID CB2 RECEPTOR BLOCKING AGENT; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CASTOR OIL; LOPERAMIDE; N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL)PYRAZOLE 3 CARBOXAMIDE; NALOXONE; OPIATE ANTAGONIST; RECEPTOR SUBTYPE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEFECATION; DIARRHEA; DRUG ANTAGONISM; ENANTIOMER; INTESTINE MOTILITY; INTESTINE SECRETION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE;

EID: 0032803098     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00673-1     Document Type: Article

References (28)

1. Albasan H., Soldani G., Brown D.R. Synthetic cannabinoids potentiate electrically-induced contractions in porcine ileum in vitro. Pharm. Res. 39:1999;5. (Supplement).
2. Calignano A., La Rana G., Makryannis A., Lin S.Y., Beltramo M., Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol. 340:1997;R7-R8.
3. Colombo G., Agabio R., Lobina C., Reali R., Gessa G.L. Cannabinoid modulation of intestinal propulsion in mice. Eur. J. Pharmacol. 344:1998;67-69.
4. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263:1992;1118-1126.
5. Croci T., Bianchetti A. Stimulation of faecal excretion in rats by α-adrenergic antagonist. J. Pharm. Pharmacol. 121:1992;1557-1566.
6. 1 receptors in human ileum. Br. J. Pharmacol. 125:1998;1393-1396.
7. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
8. Gérard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279:1991;129-134.
9. 2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 339:1997;53-61.
10. Grinspoon L., Bakalar J.B. Marijuana: The Forbidden Medicine. 1993;Yale University Press, Yale, CT.
11. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
12. Izzo A.A., Gaginella T.S., Mascolo N., Capasso F. Recent findings on the mode of action of laxatives: the role platelet activating factor and nitric oxide. Trends Pharmacol. Sci. 19:1998;403-405.
13. 1 receptor. Br. J. Pharmacol. 124:1998;1363-1368.
14. 1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;65-70.
15. Kaminski N.E., Abood M., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42:1992;736-742.
16. 1 receptors. Eur. J. Pharmacol. 334:1997;R1-R2.
17. 2 receptors. Br. J. Pharmacol. 124:1998;619-622.
18. Mascolo N., Izzo A.A., Barbato F., Capasso F. Inhibitors of nitric oxide synthetase prevent castol-oil-induced diarrhoea in the rat. Br. J. Pharmacol. 108:1993;861-864.
19. Matsuda L.A., Lolait S.J., Brownstein B.J., Young A.C., Bonner T.L. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
20. McGregor I.S., Issikidis C.N., Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol. Biochem. Behav. 53:1996;657-664.
21. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to a cannabinoid receptor. Biochem. Pharmacol. 50:1995;83-90.
22. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
23. 2 receptors. Pharmacol. Ther. 74:1997;129-180.
24. 1 receptors in guinea-pig small intestine. Br. J. Pharmacol. 118:1996;2199-2205.
25. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Breliere J.C., Le Fur G. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
26. 2 cannabinoid receptors. J. Pharmacol. Exp. Ther. 284:1998;644-650.
27. Ross R.A., Brockie H.C., Fernando S.R., Saha B., Razdan R.K., Pertwee R.G. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br. J. Pharmacol. 125:1998;1345-1351.
28. Schlicker E., Timm J., Gothert M. Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;791-795.